You can buy or sell SLNO and other stocks, options, ETFs, and crypto commission-free!
Soleno Therapeutics, Inc. engages in the development and commercialization of novel therapeutics for the treatment of rare diseases. It markets CoSense End-Tidal Carbon Monoxide monitor, which measures ETCO and is used by hospitals to detect hemolysis in newborns. Read More The company was founded on August 25, 1999 and is headquartered in Redwood City, CA.
Redwood City, California
52 Week High
52 Week Low
Yahoo FinanceMay 13
Soleno Therapeutics Provides Corporate Update and Reports First Quarter 2019 Financial Results
REDWOOD CITY, Calif., May 13, 2019 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today provided a corporate update, and reported financial results for the three months ended March 31, 2019. “Enrollment in our Phase III DESTINY PWS trial evaluating Diazoxide Choline Controlled-Release (DCCR) tablets for the treatment of Prader-Willi Syndrome (PWS) continues to progress,” said Ani...
-$0.29 per share
-$0.22 per share